Probiotics for Depression in Cancer Patients
Launched by ARISTOTLE UNIVERSITY OF THESSALONIKI · Jul 9, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of probiotics (beneficial bacteria) on depression and anxiety in cancer patients who are undergoing chemotherapy. Researchers believe that the balance of bacteria in our gut, known as the gut microbiome, plays a crucial role in our mental health. Specifically, some types of probiotics may help improve mood and reduce anxiety by positively influencing this gut-brain connection. The goal of the study is to see if taking these probiotics can help improve the quality of life for patients dealing with depression during their cancer treatment.
To participate in this trial, individuals need to be between 18 and 85 years old, have a confirmed diagnosis of digestive tract cancer that has been surgically treated, and be currently receiving chemotherapy. Participants will need to provide informed consent and be able to understand the Greek language. They should not have pre-existing psychiatric disorders or be taking other probiotic supplements. Those who join can expect to receive probiotics and be monitored for changes in their mood and overall well-being throughout the study. This trial is an opportunity to explore new ways to support mental health in cancer patients during treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 and \<85
- • Histologically confirmed diagnosis of digestive tract malignancy, the tumor having been surgically resected and the patient currently undergoing chemotherapy sessions
- • Informed consent obtained to participate in the study
- Exclusion Criteria:
- • Not understanding the Greek language
- • Dementia
- • Pre-existing psychiatric disorders
- • Already receiving probiotic supplements (apart from yoghurt)
- • Participation in another clinical trial
- • Consumption of less than the 90% of treatment sachets/doses (verified by the sachets returned)
- • Those having received during hospitalization other probiotic formulations
About Aristotle University Of Thessaloniki
Aristotle University of Thessaloniki (AUTH) is a prestigious institution in Greece, renowned for its commitment to advancing knowledge and innovation in the field of clinical research. As a leading academic sponsor of clinical trials, AUTH leverages its extensive resources and expertise to conduct rigorous studies that contribute to the understanding of various medical conditions and the development of novel therapeutic interventions. The university fosters collaboration among multidisciplinary teams, ensuring adherence to the highest ethical standards and regulatory requirements while promoting scientific excellence and enhancing patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloníki, , Greece
Patients applied
Trial Officials
Katerina Kotzampassi, Dr.
Study Director
Aristotle University of Thessaloniki, Greece
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported